Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18342663 | 0.71 | EGFR (0.33) | EGFR | |
| SCHEMBL29808187 | 0.71 | MAPK1 (0.35) | EGFR | |
| SCHEMBL656316 | 0.71 | EGFR (0.36) | EGFR | |
| SCHEMBL6674194 | 0.71 | MAPK1 (0.35) | EGFR | |
| SCHEMBL5265133 | 0.67 | MEN1 (0.35) | EGFR | |
| SCHEMBL15935249 | 0.67 | MRGPRX1 (0.38) | EGFR | |
| SCHEMBL6495650 | 0.66 | EGFR (0.39) | EGFR | |
| SCHEMBL29728017 | 0.66 | ALDH1A1 (0.42) | — | |
| SCHEMBL4908387 | 0.66 | ALDH1A1 (0.42) | — | |
| SCHEMBL6483330 | 0.66 | SELE (0.51) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059926-A | Heterocyclic degradation determinants for target protein degradation | C4医药公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | EGFR 1224/4885 |
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | EGFR 230/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | EGFR 278/4885 |
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | EGFR 219/4885 |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | STUB1, MDM2, UBE3A | EGFR 850/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | EGFR 208/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | EGFR 413/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | EGFR 850/4885 |
| US-20230095223-A1 | SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | EGFR 793/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | EGFR 1224/4885 |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | EGFR 553/4885 |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | EGFR 234/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | EGFR 234/4885 |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | CRBN, CBL, STUB1 | EGFR 674/4885 |
| US-20220313827-A1 | SUBSTITUTED PIPERIDINE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, NEDD4 | EGFR 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.